Literature DB >> 35481910

Molecular pathogenesis and emerging targets of gastric adenocarcinoma.

Abby Ivey1, Hillary Pratt1, Brian A Boone1,2.   

Abstract

Gastric adenocarcinoma (GC) is a devastating disease and is the third leading cause of cancer deaths worldwide. This heterogeneous disease has several different classification systems that consider histological appearance and genomic alterations. Understanding the etiology of GC, including infection, hereditary conditions, and environmental factors, is of particular importance and is discussed in this review. To improve survival in GC, we also must improve our therapeutic strategies. Here, we discuss new targets that warrant further exploration.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  Her2; angiogenesis; gastric cancer; immunotherapy

Mesh:

Year:  2022        PMID: 35481910      PMCID: PMC9069999          DOI: 10.1002/jso.26874

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   2.885


  171 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.

Authors:  Brian A Boone; Nathan Bahary; Amer H Zureikat; A James Moser; Daniel P Normolle; Wen-Chi Wu; Aatur D Singhi; Phillip Bao; David L Bartlett; Lance A Liotta; Virginia Espina; Patricia Loughran; Michael T Lotze; Herbert J Zeh
Journal:  Ann Surg Oncol       Date:  2015-04-24       Impact factor: 5.344

3.  Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

Authors:  Peter C Thuss-Patience; Manish A Shah; Atsushi Ohtsu; Eric Van Cutsem; Jaffer A Ajani; Hugo Castro; Wasat Mansoor; Hyun Cheol Chung; Gyorgy Bodoky; Kohei Shitara; Gail D Lewis Phillips; Tina van der Horst; Marie-Laurence Harle-Yge; Betsy L Althaus; Yoon-Koo Kang
Journal:  Lancet Oncol       Date:  2017-03-23       Impact factor: 41.316

4.  Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Authors:  J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

Review 5.  The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature.

Authors:  Rudolf Repak; Darina Kohoutova; Miroslav Podhola; Stanislav Rejchrt; Marek Minarik; Lucie Benesova; Michal Lesko; Jan Bures
Journal:  Gastrointest Endosc       Date:  2016-06-23       Impact factor: 9.427

6.  Upper gastrointestinal cancer in familial adenomatous polyposis.

Authors:  D G Jagelman; J J DeCosse; H J Bussey
Journal:  Lancet       Date:  1988-05-21       Impact factor: 79.321

7.  Identification of gastric cancer stem cells using the cell surface marker CD44.

Authors:  Shigeo Takaishi; Tomoyuki Okumura; Shuiping Tu; Sophie S W Wang; Wataru Shibata; Ramanathan Vigneshwaran; Shanisha A K Gordon; Yutaka Shimada; Timothy C Wang
Journal:  Stem Cells       Date:  2009-05       Impact factor: 6.277

8.  Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

Authors:  Y-J Bang; E Yañez Ruiz; E Van Cutsem; K-W Lee; L Wyrwicz; M Schenker; M Alsina; M-H Ryu; H-C Chung; L Evesque; S-E Al-Batran; S H Park; M Lichinitser; N Boku; M H Moehler; J Hong; H Xiong; R Hallwachs; I Conti; J Taieb
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

9.  Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Authors:  Kohei Shitara; Eric Van Cutsem; Yung-Jue Bang; Charles Fuchs; Lucjan Wyrwicz; Keun-Wook Lee; Iveta Kudaba; Marcelo Garrido; Hyun Cheol Chung; Jeeyun Lee; Hugo Raul Castro; Wasat Mansoor; Maria Ignez Braghiroli; Nina Karaseva; Christian Caglevic; Luis Villanueva; Eray Goekkurt; Hironaga Satake; Peter Enzinger; Maria Alsina; Al Benson; Joseph Chao; Andrew H Ko; Zev A Wainberg; Uma Kher; Sukrut Shah; S Peter Kang; Josep Tabernero
Journal:  JAMA Oncol       Date:  2020-10-01       Impact factor: 31.777

10.  Meat intake and risk of gastric cancer in the Stomach cancer Pooling (StoP) project.

Authors:  Ana Ferro; Valentina Rosato; Matteo Rota; Ana Rute Costa; Samantha Morais; Claudio Pelucchi; Kenneth C Johnson; Jinfu Hu; Domenico Palli; Monica Ferraroni; Zuo-Feng Zhang; Rossella Bonzi; Guo-Pei Yu; Bárbara Peleteiro; Lizbeth López-Carrillo; Shoichiro Tsugane; Gerson Shigueaki Hamada; Akihisa Hidaka; David Zaridze; Dmitry Maximovitch; Jesus Vioque; Eva M Navarrete-Munoz; Nuria Aragonés; Vicente Martín; Raúl Ulisses Hernández-Ramírez; Paola Bertuccio; Mary H Ward; Reza Malekzadeh; Farhad Pourfarzi; Lina Mu; Malaquias López-Cervantes; Roberto Persiani; Robert C Kurtz; Areti Lagiou; Pagona Lagiou; Paolo Boffetta; Stefania Boccia; Eva Negri; M Constanza Camargo; Maria Paula Curado; Carlo La Vecchia; Nuno Lunet
Journal:  Int J Cancer       Date:  2019-11-22       Impact factor: 7.316

View more
  3 in total

1.  KLF10 Functions as an Independent Prognosis Factor for Gastric Cancer.

Authors:  Yueh-Min Lin; Kun-Tu Yeh; Chung-Min Yeh; Maw-Soan Soon; Li-Sung Hsu
Journal:  Medicina (Kaunas)       Date:  2022-05-26       Impact factor: 2.948

Review 2.  Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers.

Authors:  Jose J G Marin; Maria J Monte; Rocio I R Macias; Marta R Romero; Elisa Herraez; Maitane Asensio; Sara Ortiz-Rivero; Candela Cives-Losada; Silvia Di Giacomo; Javier Gonzalez-Gallego; Jose L Mauriz; Thomas Efferth; Oscar Briz
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

3.  Identification of cuproptosis-associated IncRNAs signature and establishment of a novel nomogram for prognosis of stomach adenocarcinoma.

Authors:  Wei Yu; Hongqi Huo; Zhixin You; Rong Lu; Tianci Yao; Jing Huang
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.